Repare Therapeutics Inc. reported its financial results for the second quarter ended June 30, 2025. The company's revenue from collaboration agreements was $0.25 million, a decrease from $1.073 million in Q2 2024. The net loss for the quarter significantly narrowed to $(16.744) million, compared to $(34.774) million in the prior year period.
Research and development expenses decreased to $14.283 million in Q2 2025 from $30.075 million in Q2 2024, and general and administrative expenses fell to $6.029 million from $8.317 million. The company also recognized a $5.666 million gain on the sale of technology and other assets, contributing to the narrowed net loss.
As of June 30, 2025, Repare held $109.5 million in cash, cash equivalents, and marketable securities. The company continues to explore strategic alternatives and partnerships, including the recent worldwide licensing agreement with Debiopharm for lunresertib and the out-licensing of early-stage discovery platforms to DCx. Initial data from the LIONS and POLAR trials are expected in the fourth quarter of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.